NCT02474420

Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients

The Use of the Calcium Channel Blocker Amlodipine as an Adjuvant Treatment to Iron Chelation for the Prevention of Iron Overload Cardiomyopathy in Patients With Thalassemia

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Kevin H.M. Kuo, MD, MSc, FRCPC · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, open label, two arms superiority trial of a representative population of patients with a primary diagnosis of transfusion dependent thalassemia with evidence of moderate cardiac iron overload, defined as an average T2\* MRI parameter at the mid inter-ventricular septum between 10 and 20ms.

Detailed description

Selection of Study Population: The study will enroll 60 adult subjects with transfusion dependent thalassemia receiving deferasirox iron chelation therapy. All eligible subjects will be asked to provide informed consent before participating in the study. Randomization: Subjects will be randomized in a 1:1 ratio to either continuation of their DFX (control arm) or a combination of DFX plus amlodipine (amlodipine arm). Treatment: Subjects randomized to the amlodipine arm will receive open label medication (amlodipine) starting at 2.5mg/day and up-titrated by 2.5mg every 7-14 days with the goal of reaching 10mg/day. DFX dose in either arm will not be adjusted unless it was deemed unsafe to remain on the same dose of DFX by the treating physician (significant side effects, lack of efficacy or over-chelation) or T2\* drops below 8 ms. Safety Assessment: Weekly or fortnightly amlodipine titration will be conducted by the research physician in-clinic, based on blood pressure, tolerability, and presence or absence of side-effects. Adverse Events will be assessed at every visit after the first dose through to the last subject visit. Efficacy Assessment: the efficacy of amlodipine combined to standard chelation therapy will be assessed by cardiac T2\*MRI, done at baseline and 12 months post treatment.

Conditions

• Beta-Thalassemia
• Iron Overload

Interventions

Type	Name	Description
DRUG	Amlodipine	amlodipine titrated up to 10 mg daily or maximum tolerated dose, whichever comes first
DRUG	Deferasirox	Deferasirox administered per standard of care by the treating physician

Timeline

• Start date: 2015-06-01
• Primary completion: 2017-06-01
• Completion: 2018-06-01
• First posted: 2015-06-17
• Last updated: 2016-10-26

Locations

1 site across 1 country: Canada